Hilmara Hélia de Sousa Amaral, Talita Magalhães Rocha, Emmanuel Vinicius Oliveira Araújo, Ana Bruna de Araújo, Antonio Marcos Esmeraldo Bezerra, Janaina Serra Azul Monteiro Evangelista, Juvenia Bezerra Fontenele, Márcia Valéria Pitombeira Ferreira, Luzia Kalyne Almeida Moreira Leal
{"title":"Protective Effects of the Standardized Extract of <i>Amburana cearensis</i> in an Experimental Model of Severe Asthma: Suppression of Airway Inflammation and Modulation of Neutrophil Function.","authors":"Hilmara Hélia de Sousa Amaral, Talita Magalhães Rocha, Emmanuel Vinicius Oliveira Araújo, Ana Bruna de Araújo, Antonio Marcos Esmeraldo Bezerra, Janaina Serra Azul Monteiro Evangelista, Juvenia Bezerra Fontenele, Márcia Valéria Pitombeira Ferreira, Luzia Kalyne Almeida Moreira Leal","doi":"10.1155/adpp/7371746","DOIUrl":"https://doi.org/10.1155/adpp/7371746","url":null,"abstract":"<p><p><i>Amburana cearensis</i> A.C. Smith (Fabaceae) is traditionally used in Brazilian medicine for the treatment of asthma; however, its effects in experimental models of asthma exacerbation remain poorly understood. This study evaluated the effects of a standardized dried extract of <i>A. cearensis</i> (DEAC) and its chemical constituents-coumarin (CM) and vanillic acid (VA)-on airway inflammation in a murine model of ovalbumin (OVA) + lipopolysaccharide (LPS)-induced asthma exacerbation and on human neutrophil activation. DEAC was characterized by high-performance liquid chromatography with photodiode array detection (HPLC-PDA) (markers: CM, VA, and amburoside). BALB/c mice were sensitized and challenged with OVA + LPS and treated with DEAC (100 mg/kg) and CM. On Day 26, bronchoalveolar lavage fluid (BALF) and lungs were analyzed for total and differential leukocytes, cytokines interleukin-4 (IL-4) and tumor necrosis factor-<i>α</i> (TNF-<i>α</i>), and histopathological changes. The effects of DEAC, CM, and VA on phorbol 12-myristate 13-acetate (PMA)-induced human neutrophil activation were assessed through myeloperoxidase release and reactive oxygen species (ROS) production by chemiluminescence. OVA + LPS challenge induced severe airway inflammation, characterized by increased leukocyte recruitment, predominance of neutrophils, elevated IL-4 and TNF-<i>α</i> levels, and mucus hypersecretion. DEAC markedly reduced total leukocyte accumulation, restored the mononuclear cell proportion, and decreased neutrophil and eosinophil infiltration, with effects comparable to dexamethasone. CM reduced neutrophil accumulation without affecting total leukocytes. Lung histology confirmed decreased inflammation and mucus production. DEAC also lowered IL-4 and TNF-<i>α</i> levels. DEAC, CM, and VA inhibited neutrophil degranulation and ROS generation without affecting cell viability. These findings demonstrate the anti-inflammatory potential of <i>A. cearensis</i> and support its traditional use as an adjuvant therapy for asthma within Brazilian public phytotherapy programs.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"7371746"},"PeriodicalIF":2.9,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149416742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A B M Ashraful, Md Sabbir Hossain, Farhad Hossain, Joy Sarker, Md Najem Uddin, Aziz Abdur Rahman, Md Golam Sadik, Mamunur Rashid, A H M Khurshid Alam
{"title":"Anti-Inflammatory and Antinociceptive Potential of Phaeocaulisin H From <i>Curcuma wilcockii</i> Rhizomes (<i>Zingiberaceae</i>) in In Vitro, In Vivo, and In Silico Studies.","authors":"A B M Ashraful, Md Sabbir Hossain, Farhad Hossain, Joy Sarker, Md Najem Uddin, Aziz Abdur Rahman, Md Golam Sadik, Mamunur Rashid, A H M Khurshid Alam","doi":"10.1155/adpp/2384820","DOIUrl":"10.1155/adpp/2384820","url":null,"abstract":"<p><p><i>Curcuma wilcockii</i>, a lesser-explored member of the Zingiberaceae family, has been traditionally used in folk medicine, but its phytochemical compositions and pharmacological activities remain poorly investigated. This study evaluates the anti-inflammatory and antinociceptive potential of phaeocaulisin H (PN-H), a guaiane-type sesquiterpene newly isolated from <i>C. wilcockii</i> rhizomes, using in vitro, in vivo, and in silico approaches. In vitro activity was assessed using heat-induced RBC hemolysis and egg albumin denaturation assays. In vivo anti-inflammatory effects were evaluated using carrageenan-induced paw edema, and antinociceptive activity was assessed using acetic acid-induced writhing and formalin-induced licking tests. The COX-2 docking was performed using PyRx and Biovia Discovery Studio, and pharmacokinetic properties were evaluated using SwissADME. PN-H was isolated and characterized by LC-MS, <sup>1</sup>H, <sup>13</sup>C, and 2D-NMR. It significantly reduced hemolysis (93.55%) and protein denaturation (80.86%) at a concentration of 25 μg/mL. It inhibited paw edema by 32.61% and 50% at the doses of 10 and 20 mg/kg body weight (b.w.), respectively. In the writhing test, PN-H showed 50.93% and 79.13% (<i>p</i> < 0.0001) inhibition, whereas in the formalin test, it reduced early-phase licking by 56.77% and 70.32% and late-phase licking by 52.78% and 77.78% (<i>p</i> < 0.001). Docking studies revealed a favorable predicted interaction with COX-2, while ADME analysis predicted acceptable drug-likeness. To the best of our knowledge, this study reports for the first time the isolation of PN-H from <i>C. wilcockii</i> and provides evidence of its anti-inflammatory and antinociceptive activities. The findings support further molecular and pharmacological investigation of PN-H as a potential anti-inflammatory candidate.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"2384820"},"PeriodicalIF":2.9,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13748800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"From Mucin to Smart Medicine: Engineering Mucin-Based Biomaterials for Advanced and Responsive Drug Delivery.","authors":"Alaa A Abudayah","doi":"10.1155/adpp/3233459","DOIUrl":"10.1155/adpp/3233459","url":null,"abstract":"<p><p>Mucin, a highly glycosylated macromolecular component of mucus, has traditionally been regarded as a biological barrier that restricts drug transport across mucosal surfaces. Growing evidence, however, has repositioned mucin as a functional and engineerable biomaterial with distinctive potential for advanced drug delivery. This review examines the evolution of mucin-based delivery systems from native mucin and bulk matrices to engineered hydrogels, hybrid materials, micro- and nanoparticles, and intrinsically glycosylated nanocarriers such as mucosomes. Particular emphasis is placed on the relationship between mucin molecular architecture and pharmaceutical functionality and on the engineering strategies used to control its material properties, including chemical modification, crosslinking, polymer hybridization, nanoscale assembly, and molecular programming. These approaches have progressively transformed mucin-based systems from passive drug reservoirs into environmentally responsive and increasingly programmable platforms capable of controlled release, molecular recognition, and on-demand therapeutic responses. Emerging applications in mucosal and ocular delivery, antimicrobial and biofilm therapy, biologics, and nucleic acid therapeutics further demonstrate the expanding pharmaceutical potential of mucin. Nevertheless, clinical translation remains constrained by source-dependent heterogeneity, variability in glycosylation and purification, batch-to-batch reproducibility, stability, sterilization, scalable manufacturing, and limited in vivo validation. Future progress will require better-defined mucin materials, standardized characterization and manufacturing, rigorous safety and efficacy assessment, and demonstration of clear therapeutic advantages over established delivery systems. Collectively, advances in mucin engineering, glycoengineering, nanotechnology, and molecular programming may enable the transition of mucin from a biological barrier component to a responsive, programmable, and clinically relevant platform for smart drug delivery.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"3233459"},"PeriodicalIF":2.9,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13748809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laxmi Sen Thakuri, Ducdat Le, Narayan Sah Sonar, Hye Bin Park, Laxman Subedi, Ki-Sun Lee, Jeong-Ho Shon, Jin Woo Park, Mina Lee, Dong Young Rhyu
{"title":"Pear Peel-Enriched Residue Extract Attenuates Ethanol-Induced Liver Injury Through Regulation of Antioxidant Signaling and Lipid Metabolism.","authors":"Laxmi Sen Thakuri, Ducdat Le, Narayan Sah Sonar, Hye Bin Park, Laxman Subedi, Ki-Sun Lee, Jeong-Ho Shon, Jin Woo Park, Mina Lee, Dong Young Rhyu","doi":"10.1155/adpp/6147577","DOIUrl":"10.1155/adpp/6147577","url":null,"abstract":"<p><p>Excessive alcohol consumption induces progressive liver injury through oxidative stress, lipid accumulation, and inflammation, primarily driven by dysregulated ethanol (EtOH) metabolism. Given the growing interest in plant-derived phytochemicals for hepatoprotection, pear (<i>Pyrus pyrifolia</i>) has attracted attention due to its antioxidant and lipid-regulating properties; however, the bioactive fractions and mechanisms underlying the hepatoprotective effects of pear peel-enriched residue extracts (PPE) remain unclear. Therefore, we evaluated the hepatoprotective potential of PPE against EtOH-induced liver injury using in vitro, in vivo, and in silico approaches. In HepG2 cells, PPE reduced oxidative stress, restored cell viability, and reduced intracellular EtOH and acetaldehyde levels more effectively than pear extract, with efficacy comparable to silymarin. In EtOH-treated C57BL/6 mice, PPE attenuated liver injury markers, reduced hepatic lipid accumulation, and improved histopathological alterations. PPE also modulated the expression of proteins associated with oxidative stress and lipid metabolism. GNPS-FBMN analysis putatively annotated over 120 phytochemicals (or metabolites), and in silico analyses suggested potential interactions between selected metabolites and proteins involved in EtOH metabolism and lipid regulation. These findings suggest that PPE shows hepatoprotective potential and warrants further investigation as a potential candidate for the mitigation of alcohol-associated liver disease.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"6147577"},"PeriodicalIF":2.9,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13735535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yara Nabeel Al-Salhi, Hani Naseef, Moammal Qurt, Abdallah Damin Abukhalil, Abdullah K Rabba, Israr Sabri, Fuad Al-Rimawi
{"title":"Self-Microemulsifying Drug Delivery System: Liquid-Filled Gelatin Capsules of Atorvastatin and Ezetimibe.","authors":"Yara Nabeel Al-Salhi, Hani Naseef, Moammal Qurt, Abdallah Damin Abukhalil, Abdullah K Rabba, Israr Sabri, Fuad Al-Rimawi","doi":"10.1155/adpp/8642343","DOIUrl":"10.1155/adpp/8642343","url":null,"abstract":"<p><p>Atorvastatin (ATV) and ezetimibe (EZE) are BCS Class II drugs with low oral bioavailability (14% and 35%, respectively) attributed to poor aqueous solubility and extensive first-pass metabolism. Although the two drugs act synergistically to lower cholesterol, their combination into a single delivery system is complicated by differing physicochemical properties. This study aimed to develop and characterize a self-microemulsifying drug delivery system (SMEDDS) coloaded with ATV and EZE, encapsulated in an Empo Caps LP + size 00 capsule, to improve their dissolution and permeability. Pseudoternary phase diagrams were constructed to identify microemulsion regions, and candidate formulations were screened by droplet size, polydispersity index, refractive index, and viscosity. Four formulations (ME#22, ME#26, ME#31, and ME#35) met the physical acceptance criteria, including a polydispersity index (PDI) within its theoretically valid 0-1 range; a fifth trial (ME#12) was excluded on this basis. Formula 31-containing 14.96% triacetin, 39.89% Tween 80%, and 19.94% PEG 400 (oil:surfactant/cosurfactant ratio 2:8; surfactant:cosurfactant ratio 2:1)-showed the highest drug loading (ATV 3.95 ± 0.35 mg/mL; EZE 3.04 ± 0.06 mg/mL), a droplet size of 74.15 ± 1.68 nm, PDI of 0.34 ± 0.02, refractive index of 1.372, and viscosity of 310 ± 9.58 cP, with assay values of 104.6% (ATV) and 104.9% (EZE). This formulation demonstrated faster in vitro dissolution than the commercial reference product (Atozet) across all tested media and significantly greater ex vivo intestinal permeability than plain drug suspension (<i>p</i> < 0.05 from 90 min onward). In conclusion, an ATV-/EZE-loaded SMEDDS encapsulated in an Empo Caps LP + size 00 capsule was successfully developed and showed improved in vitro dissolution and ex vivo permeability relative to the marketed product, supporting its potential as an alternative oral delivery strategy for this drug combination.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"8642343"},"PeriodicalIF":2.9,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13735739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Siti Marliana Jasni, Yiizamy Suffian, Nor Hisam Zamakshshari, Erna-Zulaikha Dayang
{"title":"Hydroxychavicol-Rich <i>Piper betle</i> Extracts Attenuate TNFα-Driven Endothelial Inflammatory Response by Modulating Adhesion Molecules and Cytokine Release.","authors":"Siti Marliana Jasni, Yiizamy Suffian, Nor Hisam Zamakshshari, Erna-Zulaikha Dayang","doi":"10.1155/adpp/7056593","DOIUrl":"10.1155/adpp/7056593","url":null,"abstract":"<p><p>Atherosclerosis is a chronic inflammatory disorder that involves endothelial dysfunction and accumulation of inflammatory cells in the vessel intima. Approximately 32% of global mortality is attributed to cardiovascular diseases, with atherosclerosis playing a major role. Endothelial dysfunction is a key hallmark of atherosclerosis, with key mediator tumor necrosis factor-α (TNF-α) driving endothelial-monocyte interactions that further lead to adverse cardiovascular events. Hydroxychavicol, a phenolic compound enriched in <i>Piper betle</i> (PB), methanolic and chloroform extracts, has demonstrated anti-inflammatory activity, yet its effects on endothelial activation remain insufficiently characterized. Therefore, this study aimed to investigate the endothelial-protective effects of hydroxychavicol-rich PB methanol (PB-M) and chloroform (PB-C) extracts by evaluating their impact on the expression of adhesion molecules and proinflammatory cytokines in TNF-α-induced human umbilical vein endothelial cells (HUVECs). HPLC was performed to confirm the presence and determine the amount of hydroxychavicol in both PB-M and PB-C. The cytotoxicity effects of both extracts were first assessed by MTT assay. HUVECs were pretreated with NF-κB inhibitor BAY11-7082, PB-M, or PB-C before being exposed to TNF-α for 4 h. Adhesion molecules and cytokines expression were measured by Western blot and ELISA, respectively. Both PB-M and PB-C were shown to contain hydroxychavicol, yet PB-C has about 3.8 times higher levels. MTT assays yielded IC<sub>50</sub> values of 128.9 µg/mL for PB-M and 18.59 µg/mL for PB-C, while HUVEC morphology remained normal at 100 µg/mL PB-M and 20 µg/mL PB-C. Both extracts displayed dose-dependent suppressing effects on TNF-α-induced E-selectin, VCAM-1, and ICAM-1 expression. PB-M resulted in a pronounced inhibition of IL-6, IL-8, and MCP-1, while PB-C displayed cytokine-selective suppressive effects. In conclusion, both PB-M and PB-C attenuated TNF-α-induced endothelial inflammation, with PB-C acting at lower effective doses but PB-M providing broader anti-inflammatory suppression, suggesting that their different phytochemical compositions and possible synergistic interactions beyond hydroxychavicol may contribute to their distinct bioactivities, warranting further investigations.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"7056593"},"PeriodicalIF":2.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaobing Chen, Luying Zhang, Wanying Zhang, Xueqin Wu, Kun Liu, Yuli Zhou, Yongqing Chen, Mingyue Zhu, Bo Lin, Mengsen Li
{"title":"Medicinal Compositions of Long Stephania Herb Exhibit Antilung Cancer Effects.","authors":"Xiaobing Chen, Luying Zhang, Wanying Zhang, Xueqin Wu, Kun Liu, Yuli Zhou, Yongqing Chen, Mingyue Zhu, Bo Lin, Mengsen Li","doi":"10.1155/adpp/8058846","DOIUrl":"https://doi.org/10.1155/adpp/8058846","url":null,"abstract":"<p><p>Lung cancer is one of the most common malignancies worldwide, and due to its high mortality rate and resistance to treatment, there is an urgent need to develop effective treatments with low toxicity. Long stephania herb (LSH) is a tropical herb used clinically for the treatment of inflammation and analgesia, but its antitumor effects are unknown. In this study, UHPLC-OE-MS was used to detect the chemical components of LSH; the cytotoxic effects of these chemical components on normal lung cells and non-small cell lung cancer (NSCLC) cell lines were observed in vitro cell experiments, and the inhibitory effects of LSH on the growth of NSCLC were detected in animal tumor models. The possible molecular targets of LSH for NSCLC were predicted by network pharmacology and molecular docking. The results showed that LSH has more than a thousand chemical components; at the microgram level per milliliter, it can effectively inhibit the proliferation, migration, and invasion of lung cancer A549 cells and promote apoptosis in these cells. It also can effectively inhibit the growth of tumors <i>in vivo</i> and has no significant toxic effects on normal lungs, liver, heart, and kidneys. Analysis showed that 20 pharmacodynamic components of LSH may target EGFR, PIK3CA, PIK3R1, AKT1, HSP90AA1, SRC, MAPK1, MAPK3, STAT3, JUN, and CASP3. Inhibition of the PI3K/AKT signaling pathway and proteoglycans in cancer and other signaling pathways plays an anti-NSCLC role. In conclusion, this study is the first to report the efficacy of LSH in the treatment of NSCLC, and it is a very valuable tropical medicinal plant for the treatment of lung cancer.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"8058846"},"PeriodicalIF":2.9,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13717228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149293953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Standardization and Development of Spray-Dried Chewable Tablets From the Traditional Thai Remedy \"Ya-Tard Aob-Choei\": HPLC Analysis and Comparison With Commercial Products.","authors":"Jringjai Areemit, Bungorn Sripanidkulchai, Sasipong Tipratchadaporn, Sarunya Tuntiyasawasdikul","doi":"10.1155/adpp/2822019","DOIUrl":"https://doi.org/10.1155/adpp/2822019","url":null,"abstract":"<p><strong>Ethnopharmacological relevance: </strong>The Thai traditional medicine \"Ya-Tard Aob-Choei\" (AC) is a polyherbal remedy used for the treatment of gastrointestinal disorders. Its traditional liquid dosage form has practical limitations, including inconsistent appearance and difficulties in handling and transportation. This study aimed to develop a chewable dosage form of AC with satisfactory physicochemical properties and to evaluate the retention of selected marker compounds, including gallic acid (GA), cinnamaldehyde (CMD), eugenol (EUG), and glycyrrhizic acid (GZ).</p><p><strong>Materials and methods: </strong>Formulation studies were conducted to identify suitable excipients for the preparation of AC powder and chewable tablets, and the resulting formulations were evaluated for their physicochemical properties. A validated high-performance liquid chromatography (HPLC) method was used to determine the selected marker compounds and compare the phytochemical profile of the developed formulation with liquid AC preparations, including a self-prepared reference formulation and commercially available products.</p><p><strong>Results: </strong>The formulation containing maltodextrin DE 18 at an extract-to-carrier ratio of 1:2 exhibited optimal powder characteristics for tablet production, and isomalt was identified as an effective diluent-binder for the preparation of chewable tablets with satisfactory physicochemical properties. HPLC analysis revealed compound-specific changes during conversion from the liquid-to-solid dosage form. GA was relatively well preserved (5.25 mg/dose), whereas EUG, CMD, and GZ decreased by approximately 99%, 35%, and 33%, respectively, compared with the self-prepared liquid formulation (P7).</p><p><strong>Conclusion: </strong>A chewable AC tablet with satisfactory physicochemical properties was developed; however, conversion to the solid dosage form resulted in compound-specific losses, particularly of EUG. Further process optimization is required to improve the retention of volatile and heat-sensitive constituents. This formulation approach may nevertheless offer a pragmatic strategy for the development and standardization of other traditional Thai herbal medicines, although dedicated stability and sensory studies are needed to establish product stability and acceptability.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"2822019"},"PeriodicalIF":2.9,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xia Zhou, Fei Zhou, Zhenpeng Fu, Weijun Ye, Guo Li, Jason Li, Weihong Zheng, Hua-Xin Liao, Shaojie Wang, Xiaoyi Liu
{"title":"Regulatory-Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys.","authors":"Xia Zhou, Fei Zhou, Zhenpeng Fu, Weijun Ye, Guo Li, Jason Li, Weihong Zheng, Hua-Xin Liao, Shaojie Wang, Xiaoyi Liu","doi":"10.1155/adpp/2804371","DOIUrl":"10.1155/adpp/2804371","url":null,"abstract":"<p><p>Siltartoxatug-developed by Trinomab Pharmaceutical Co., Ltd., using its proprietary HitmAb® platform-is the first-in-class recombinant monoclonal antibody drug for urgent prophylaxis of tetanus approved by China National Medical Products Administration in February 2025, which addresses the critical unmet need to substitute blood-derived passive immunization preparations for prevention of tetanus. The nonclinical pharmacokinetic and immunogenicity study of siltartoxatug was designed and conducted in strict compliance with global regulatory guidelines for initiating the first-in-human clinical trials. Herein, we report the comprehensive findings from this study. Twenty-four naive cynomolgus monkeys (<i>Macaca fascicularis</i>) were randomly assigned to four groups each with 6 animals. Monkeys in Group 1 received intravenous infusion of siltartoxatug at 1 mg/kg. Monkeys in Groups 2, 3, and 4 received intramuscular injection of siltartoxatug at dose of either 1 mg/kg, 3 mg/kg, or 10 mg/kg. Blood samples were collected over 57 days post-administration, and serum drug concentrations and anti-drug antibody levels were determined with validated methods. Results showed that intramuscular administration of siltartoxatug exhibited favorable pharmacokinetic characteristics: primarily systemic distribution with high bioavailability (88.0% at 1 mg/kg) and low apparent volume of distribution (58.7-69.4 mL/kg), prolonged elimination half-life (11.7-12.4 days), short mean time to maximum concentration (1.2-2.7 days), and dose-dependent systemic exposure without significant sex differences. Additionally, minimal anti-drug antibody responses were observed. These findings underpinned greater predictability for its clinical translation and informed its first-in-human development.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"2804371"},"PeriodicalIF":2.9,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlo Oliviero, Alessandra Fusco, Enrica Giustino, Roberta Palladino, Eugenia Romano, Barbara Maglione, Antonella D'Agostino, Chiara Schiraldi
{"title":"Evaluation of Biological Effect of <i>Triticum vulgare</i> Extract Compared With Hyaluronic Acid in In Vitro Tissue Models.","authors":"Carlo Oliviero, Alessandra Fusco, Enrica Giustino, Roberta Palladino, Eugenia Romano, Barbara Maglione, Antonella D'Agostino, Chiara Schiraldi","doi":"10.1155/adpp/8857215","DOIUrl":"10.1155/adpp/8857215","url":null,"abstract":"<p><p>Plant extracts and microbial-derived molecules, particularly oligo- and polysaccharides, are known to promote tissue repair. <i>Triticum vulgare</i> extract (TVE), derived from germinated whole plants and utilized in medical devices, is rich in bioactive molecules comprised of oligo- and polysaccharides with diverse biological properties beneficial for wound repair. This study investigates the biochemical mechanisms underlying TVE's proregenerative activity in vitro effects, comparing it with hyaluronic acid (HA), a gold standard in wound healing. Preliminary results showed that TVE has scavenging properties/antioxidant activity also at lower concentrations with respect to HA that has long been recognized for these properties (Galvez-Martin et al.). In vitro assays evaluated cell proliferation, migration, extracellular matrix biomarkers, and responses to stress in 2D and 3D models. TVE significantly enhanced keratinocyte migration, reaching approximately 50% wound closure in less than 20 h, whereas the untreated control required about 30 h to achieve the same level of closure. Moreover, TVE performed better than HA at low concentrations, while both treatments improved HDF proliferation and ECM biomarker expression. More specifically, COL1 expression was upregulated by 2.3-fold relative to the control, showing an effect comparable to that induced by HA (2.8-fold). Conversely, ELS expression exhibited a 2.0-fold increase in response to TVE and a 2.6-fold increase following HA treatment compared with the control. In addition, the extract significantly increased HBD-2 expression by 2-fold relative to the control, a novel finding that may be relevant, given the role of this antimicrobial peptide in innate immunity, inflammation regulation, and wound repair. Under stressful conditions, including dehydration and exposure to reactive oxygen species, TVE showed protective effects comparable to HA in both HDF and HaCaT cells. 3D skin models, including those treated with LPS, confirmed the results of 2D assays, further validating TVE's biological properties. Overall, these studies demonstrate that this extract exerts biological effects comparable to pharmaceutical HA in several in vitro skin models. These findings further support the potential application of TVE in wound management and skin regenerative approaches.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2026 ","pages":"8857215"},"PeriodicalIF":2.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}